Associate Professor Christina Bursill, South Australian Health and Medical Research Institute, Australia
A/Prof Christina Bursill (BSc (Hons 1) PhD, Adelaide University; Postdoc, Oxford University, UK) is a leader in cardiovascular biology, with a national and emerging international profile for her expertise in the biology and mechanisms of atherosclerotic plaques and mechanisms of diabetes-impaired angiogenesis and wound healing. After a six-year postdoc at The University of Oxford, she returned to Australia to lead the Immunobiology Group at the Heart Research Institute as part of a National Heart Foundation Career Development Fellowship. In 2017 A/Prof Bursill moved to Adelaide where she is Co-director of the Vascular Research Centre at South Australian Health and Medical Research Institute (SAHMRI) and a National Heart Foundation (NHF) Lin Huddleston fellow. A/Prof Bursill is Chief Investigator on the Australian Research Council, Centre of Nanoscale Biophotonics (CNBP), a $23 million grant, where she leads the “Inside blood vessels theme”. As CIA she has received >$2 million in competitive research funding in the last 3 years including NHMRC Ideas, Diabetes Australia Millennium and National Heart Foundation Vanguard grants. A/Prof Bursill has published >95 papers, supervised >15 PhD students to completion and currently leads a research team of six people. A/Prof Bursill is a board member for the Australian Cardiovascular Alliance (ACvA), the International Atherosclerosis Society and is past-President of the Australian Atherosclerosis Society (AAS, 2017-2019).
Dr Rachael Moses, University of Melbourne, Australia
Dr Rachael Moses took up the position of Research Associate at the University of Melbourne in 2021 with Professor Alastair Sloan, where she heads up the lab in the Sloan/Moses group. Rae’s interests lie in natural compound pharmaceuticals for wound healing, in particular for chronic, non-healing wounds. Additionally, she has an interest in the 3Rs (reduction, replacement, refinement), focusing on developing a 3D organotypic chronic wound model for the assessment of novel wound healing therapies. She obtained her PhD at Cardiff University, in the UK, in the field of Tissue Engineering. Continuing from her PhD studies, Rae undertook postdoctoral research focusing on the elucidation of the underlying mechanisms of action by which novel epoxy-tigliane pharmaceuticals promote preferential wound healing responses, in collaboration with QBiotics Group and QIMR Berghofer, based in Australia. This research resulted in being included as an inventor on a worldwide patent for ‘Methods and Compositions for Wound Healing’, relating to the application of epoxy-tigliane compounds in the promotion of dermal wound healing and reduced scarring.
Dr Abbas Shafiee, University of Queensland, Australia
Dr Abbas Shafiee is a Senior Research Fellow at the Herston Biofabrication Institute (The Royal Brisbane and Women’s Hospital, MNHHS), and The University of Queensland. He has a demonstrated high performing research trajectory in the Regenerative Medicine and Bioengineering arena. His research impact has been demonstrated with 67 research papers in high standing, and high impact factor journals, including but not limited to Biomaterials, The Journal of Heart and Lung Transplantation, Bone Research, Stem Cells Translational Medicine, and Small.
In 2020, Dr Shafiee started a clinical research program to develop, implement, and evaluate the applications of 3D printing, stem cell therapies, and biofabrication technologies in burn patients. Using 3D printing and stem/progenitor cell delivery, he could develop new dressing to enhances physiological wound closure with reduced scarring. He is also part of a national program aiming to develop 3D bioprinting technology to treat skin wounds. Additionally, Dr Shafiee’s team has found new ways of generating skin organoids from human pluripotent stem cells. Reconstructing the appendage-bearing skin organoids in cultures could change the way skin diseases and wounds are studied and treated.
Dr Shafiee’s authority in the field has been acknowledged by invitations to serve as Guest Editor or on the Editorial Board of leading scientific journals. He is also passionate about training the next scientific generation and healthcare professionals, and has trained several PhD, MSc, MD, and undergraduate students.
Dr Andrew Stevenson, University of Western Australia
Dr. Andrew Stevenson is a Postdoc based at the Burn Injury Research Unit at the University of Western Australia, where he has a broad focus on burn injury and a specific interest in fibroblast biology. Completing his PhD on the epigenetics of scar fibroblasts in 2016, he has been involved in a multitude of projects based on reducing fibrosis and encouraging skin regeneration, including single cell RNA sequencing of keloid scar, developing a topical lysl-oxidase based inhibitor to treat scarring (now in phase II clinical trial), and more recently, in vivo 3D bioprinting. He has a keen interest in all forms of regenerative biology, as well as driving unique applications of new technology to existing problems in the field of wound healing and scarring, and was named AWTRS early to mid-career researcher of the year in 2021.